From typo-laden code in psychedelics research to paper mills and plagiarism, we look back on some of the most notable retractions in scientific publishing this year.
The Top Retractions of 2022
The Top Retractions of 2022
From typo-laden code in psychedelics research to paper mills and plagiarism, we look back on some of the most notable retractions in scientific publishing this year.
From typo-laden code in psychedelics research to paper mills and plagiarism, we look back on some of the most notable retractions in scientific publishing this year.
University of Wollongong epidemiologist Gideon Meyerowitz-Katz speaks with The Scientist about his team’s finding that flawed and fraudulent COVID-19 research continues to be cited.
The retracted studies were coauthored by a scientist who worked on an Alzheimer’s therapy in development by Cassava Sciences, a company reportedly under investigation for providing falsified data to the FDA.
The Scientist interviewed clinical pharmacologist Clara Locher, coauthor of a new survey aimed at detecting editorial bias, regarding her team’s findings about biomedical publishing.
Illinois-based Surgisphere Corporation had a brief moment in the limelight this year following its infamous study of hydroxychloroquine. But the impact of the company’s deception reverberated across world.
The high-profile retractions of two COVID-19 studies stunned the scientific community earlier this year and prompted calls for reviews of how science is conducted, published, and acted upon. The warning signs had been there all along.
The changes, which affect the declarations authors have to sign and the peer-review process, have received a mixed response from the scientific community.
Nineteen researchers have stepped down after the journal decided not to retract a paper that they say plagiarized the work of a Johns Hopkins biomedical scientist.